Regional pharmacokinetics of 5-bromo-2'-deoxyuridine and 5-fluorouracil in dogs: Hepatic arterial versus portal venous infusions

Cancer Research

Volumn 56, Issue 20, 1996, Pages 4724-4727

  Kuan, Han Yi ^a   Smith, David E ^a   Ensminger, William D ^a,b   Knol, James A ^b   DeRemer, Susan J ^a   Yang, Zhaomin ^a   Stetson, Philip L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; FLUOROURACIL;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; DOG; FEMALE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PORTAL VEIN; PRIORITY JOURNAL;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BROMODEOXYURIDINE; DOGS; FEMALE; FLUOROURACIL; HEPATIC ARTERY; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; LIVER; MALE; PORTAL VEIN; REGIONAL BLOOD FLOW;

EID: 0029815445     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Grem, J. L Fluorinated pyrimidines. In. B. A. Chabner and J M. Collins (eds), Cancer Chemotherapy: Principles and Practice, pp. 180-224 Philadelphia: J. B. Lippincott Co., 1990
2. Calabresi, P, and Chabner, B. A. Chemotherapy of neoplastic diseases. In: A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, Ed. 8, pp. 1202-1263. New York: Pergamon Press, 1990.
3. Diasio, R. B., and Harris, B. E Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
4. Kinsella, T. J., Russo, A., Mitchell, J. B., Rowland, J., Jenkins, J, Schwade, J., Myers, C. E., Collins, J. M., Speyer, J., Komblith, P, Smith, B., Kufta, C, and Glatstein, E. A phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J. Radiat. Oncol. Biol. Phys., 10: 69-76, 1984.
5. Maybaum, J., Burton, E. C., Shelton, D. A, Jing, H-W., Dusenbury, C. E., Ensminger, W. D., and Stetson, P. L Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines. Biochem. Pharmacol., 42: 131-137, 1991.
6. Collins, J. M Pharmacologic rationale for regional drug delivery J. Clin Oncol., 2: 498-504, 1984.
7. Daly, J. M, Williams, N. N., and Torosian, M. H. Hepatic regional infusion chemotherapy. In: J J Lokich (ed.), Cancer Chemotherapy by Infusion, Ed. 2, pp. 587-598 Chicago: Precept Press, Inc., 1990.
8. Wagner, J. G, Gyves, J. W, Stetson, P. L., Walker-Andrews, S. C., Wollner, I. S., Cochran, M. K., and Ensminger, W. D. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients. Cancer Res., 46: 1499-1506, 1986.
9. Smith, D. E., Brenner, D. E., Knutsen, C. A., DeRemer, S. J., Terrio, P. A., Johnson, N. J., Stetson, P L., and Ensminger, W. D. Effect of bromodeoxyuridine and iododeoxyuridine on the pharmacokinetics of 5-fluorouracil in dogs. Drug Metab. Dispos., 21: 277-283, 1993
10. Wagner, J. G., Stetson, P. L., Knol, J. A, Andrews, J. C., Walker-Andrews, S., Knutsen, C A., Johnson, N., Prieskorn, D, Terrio, P., Yang, Z, Ganes, D., and Ensminger, W. D Steady-state arterial and hepatic venous plasma concentrations of 5-bromo-2′-deoxyuridine and 5-iodo-2′-deoxyuridine in animals: drugs which are subject to both splanchnic and extra-splanchnic elimination. Sel. Cancer Ther., 5: 193-203, 1989.
11. Ensminger, W. D., Andrews, J C., Walker-Andrews, S., Johnson, N., Wollner, I, and Stetson, P. Clinical pharmacology of hepatic arterial 5-bromo-2′-deoxyuridine (BUDR). In: W. D. Ensminger and J. L. Selam (eds), Update in Drug Delivery Systems, pp. 215-224. Mount Kisco: Futura Publishing Co, Inc., 1989.
12. Breedis, C., and Young, C. Blood supply of neoplasms in the liver. Am. J. Pathol., 30. 969-977, 1954
13. Chabner, B. A, and Myers, C. E. Clinical pharmacology of cancer chemotherapy. In: V T. DeVita Jr, S. Hellman, and S. A. Rosenberg (eds), Cancer: Principles and Practice of Oncology, Vol. 1, Ed. 3, pp. 349-395. Philadelphia: J. B. Lippincott Co., 1989.
14. Ackerman, N B., Lien, W. M, Kondi, E. S., and Silverman, N. A The blood supply of experimental liver metastases. I The distribution of hepatic artery and portal vein blood to "small" and "large" tumors. Surgery (St. Louis), 66: 1067-1072, 1969.
15. Wolmark, N., Rockette, H., Wickerham, D. L, Fisher, B., Redmond, C., Fisher, E. R, Potvin, M., Davies, R. J., Jones, J, Robidoux, A, Wexler, M, Gordon, P, Cruz, A B, Horsley, S, Nims, T. A., Thirlwell, M, Phillips, W. A., Prager, D., Stem, H. S., Lerner, H J., and Frazier, T G Adjuvant therapy of Dukes' A. B, C adenocarcinoma of the colon and portal-vein fluorouracil hepatic infusion. Preliminary Results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J. Clin. Oncol, 8: 1466-1475, 1990.
16. Knol, J. A., Stetson, P. L., Wagner, J G., Johnson, N., Yang, Z., Prieskorn, D, Terrio, P., Knutsen, C A, and Ensminger, W. D. 5-Bromo-2′-deoxyuridine incorporation into DNA in hepatic VX2 tumor-bearing rabbits. J. Surg. Res, 47: 112-116, 1989.
17. Heggie, G. D., Sommadossi, J-P., Cross, D. S, Huster, W. J, and Diasio, R. B Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
18. Au, J. L-S., Rustum, Y M., Ledesma, E. J, Mittelman, A., and Creaven. P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res., 42: 2930-2937, 1982.
19. Stetson, P. L., Shukia, U A, and Ensminger, W D Sensitive high-performance liquid chromatographic method for the determination of bromodeoxyuridine and its major metabolite, bromouracil, in biological fluids. J Chromatogr., 341: 217-222, 1985.
20. Stetson, P. L., Maybaum, J., Shukla, U. A., and Ensminger, W. D. Simultaneous determination of thymine and 5-bromouracil in DNA hydrolysates using gas chromatography-mass spectrometry with selected-ion monitoring J Chromatogr., 375: 1-9, 1986.
21. Gibaldi, M., and Perrier, D. Clearance concepts In. Pharmacokinetics, Ed. 2, pp 319-353. New York: Marcel Dekker, Inc, 1982.
22. Altman, P. L., and Dittmer, D. S Hepatic blood flow: mammals In: Biology Data Book, Ed 2, Vol. III, pp 1703-1706. Bethesda: Federation of American Societies for Experimental Biology, 1974.
23. Skerjanec, A., O'Brien, D. W., and Tam, Y. K. Hepatic blood flow measurements and indocyanine green kinetics in a chronic dog model Pharm. Res (NY), 11: 1511-1515, 1994.
24. Collins, J. M, Dedrick, R. L., King, F G, Speyer, J. L., and Myers, C. E. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes Clin. Pharmacol & Ther., 28: 235-246, 1980.
25. Ensminger, W D., Rosowsky, A., Raso, V, Levin, D. C., Glode, M., Come, S, Steele, G., and Frei, E., III A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res, 38: 3784-3792, 1978.
26. Ensminger, W D., Walker, S. C, Stetson, P. L., Wagner, J. G, Knol, J. A., Lawrence, T. S., and Andrews, J. C. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2′-deoxyuridine. Cancer Res, 54: 2121-2124, 1994.